Analyst Downgrades: Amgen, Inc., Teva Pharmaceutical Industries Ltd, and HP Inc

Analysts downwardly revised their ratings and price targets on Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (TEVA), and HP Inc (HPQ)

by Alex Eppstein

Published on Aug 25, 2016 at 10:05 AM

Analysts are weighing in on drugmakers Amgen, Inc. (NASDAQ:AMGN) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), as well as tech stock HP Inc (NYSE:HPQ). Here's a quick roundup of today's bearish brokerage notes on AMGN, TEVA, and HPQ.

  • Morgan Stanley trimmed its price target on AMGN to $198 from $199, after the U.S. Food and Drug Administration (FDA) rejected the drugmaker's request to market Parsabiv for secondary hyperparathyroidism. These developments have dropped the stock 0.5% to $169.96. However, Amgen, Inc. remains fairly close to its annual high of $176.64, touched one week ago. If options traders have their druthers, the stock will continue to drift lower. During the last 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 1.80 puts for every call -- a ratio ranking just 4 percentage points from an annual peak.
  • TEVA was dealt a legal blow yesterday, when the U.S. Patent and Trademark Office invalidated a pair of patents for multiple sclerosis drug Copaxone. The negative momentum is spilling over into today, with the stock down 0.6% at $51.30 -- with losses exacerbated by Morgan Stanley's $6 price-target cut to $63. This isn't particularly out of the ordinary for Teva Pharmaceutical Industries Ltd shares, though, as they've surrendered roughly 22% year-to-date. Losses could mount if upbeat brokerage firms begin to rethink their assessments. At present, 11 analysts rate TEVA a "buy" or better, compared to five "holds" and zero "sells" -- leaving the door wide open for potential downgrades.
  • HPQ has dropped 4.6% to trade at $13.74, pressured by the company's weak earnings forecast -- which is overshadowing better-than-expected fiscal third-quarter results. Adding fuel to the bearish fire, Maxim downgraded its rating to "hold" from "buy," and cut its target price to $15 from $17. On the other hand, at least five analysts raised their price targets on HP Inc. Technically speaking, the shares have been red-hot since their early February lows just south of $9, and are currently trying to establish a foothold at their rising 50-day moving average. Options players certainly wouldn't mind a bounce. HPQ's 10-day ISE/CBOE/PHLX call/put volume ratio of 3.83 sits 2 percentage points from a 12-month peak.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

Huge New Legal Marijuana Market Has Shortage Crisis
250 million Europeans have access to medical marijuana. There's already a shortage....
Tiffany Stock Drops as Takeover Talks Dissipate
LVMH was to acquire Tiffany & Co in a billion-dollar deal
Coty Stock Glows Up with Possible Kardashian Cosmetics Line
The trendy cosmetics company is in talks with reality TV star Kim Kardashian West over a line of beauty products
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.